Market closed
Veracyte/$VCYT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Veracyte
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
Ticker
$VCYT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
815
Website
Veracyte Metrics
BasicAdvanced
$3.2B
Market cap
-
P/E ratio
-$0.12
EPS
1.67
Beta
-
Dividend rate
Price and volume
Market cap
$3.2B
Beta
1.67
52-week high
$43.50
52-week low
$18.61
Average daily volume
846K
Financial strength
Current ratio
5.075
Quick ratio
4.592
Long term debt to equity
1.063
Total debt to equity
1.683
Interest coverage (TTM)
5,118.00%
Management effectiveness
Return on assets (TTM)
0.80%
Return on equity (TTM)
-0.83%
Valuation
Price to revenue (TTM)
7.245
Price to book
2.68
Price to tangible book (TTM)
10.32
Price to free cash flow (TTM)
54.557
Growth
Revenue change (TTM)
23.95%
Earnings per share change (TTM)
-82.22%
3-year revenue growth (CAGR)
31.58%
3-year earnings per share growth (CAGR)
-52.27%
What the Analysts think about Veracyte
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Veracyte stock.
Veracyte Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Veracyte Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Veracyte News
AllArticlesVideos
Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
Business Wire·2 weeks ago
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Veracyte stock?
Veracyte (VCYT) has a market cap of $3.2B as of December 22, 2024.
What is the P/E ratio for Veracyte stock?
The price to earnings (P/E) ratio for Veracyte (VCYT) stock is 0 as of December 22, 2024.
Does Veracyte stock pay dividends?
No, Veracyte (VCYT) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Veracyte dividend payment date?
Veracyte (VCYT) stock does not pay dividends to its shareholders.
What is the beta indicator for Veracyte?
Veracyte (VCYT) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.